News · 26 weeks95+340%
2026-03-012026-08-23
Mix4090d
- Other17(43%)
- SEC Filings14(35%)
- Insider7(18%)
- Earnings2(5%)
Latest news
25 items- SECSEC Form 6-K filed by IceCure Medical Ltd.6-K - IceCure Medical Ltd. (0001584371) (Filer)
- PRIceCure Signs Exclusive Distribution Agreement for ProSense® Cryoablation Systems in the NetherlandsAgreement expands ProSense® commercialization in the Netherlands as cryoablation advances to Phase III in the Netherlands-based independent THERMAC breast cancer cryoablation trial after achieving the highest complete ablation rate among evaluated thermal ablation technologiesCAESAREA, Israel, Aug. 24, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it has entered into an exclusive distribution agreement (the "Agreement") with Scovas Medical ("Scovas") for the distribution of IceCure's Pr
- PRWest Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer CryoablationPatients are expected to enroll in the post-marketing study in the coming weeks, following approval from the Institutional Review Board of West Cancer Center & Research Institute in Germantown, TNCAESAREA, Israel, Aug. 20, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that the Institutional Review Board (JHM-IRB) of West Cancer Center & Research Institute in Germantown, Tennessee, has granted approval for the Company's post-marketing study ("ChoICE Study") for ProSense® cryoablation in the l
- SECSEC Form EFFECT filed by IceCure Medical Ltd.EFFECT - IceCure Medical Ltd. (0001584371) (Filer)
- SECSEC Form EFFECT filed by IceCure Medical Ltd.EFFECT - IceCure Medical Ltd. (0001584371) (Filer)
- INSIDERVP, Sales for North America Good Shad was granted 131,483 units of Ordinary Shares, increasing direct ownership by 2,521% to 136,698 units (SEC Form 4)4 - IceCure Medical Ltd. (0001584371) (Issuer)
- INSIDERSEC Form 3 filed by new insider Salton David3 - IceCure Medical Ltd. (0001584371) (Issuer)
- INSIDERVP, BD & Global Marketing Tel-Tzure Tlalit Bussi was granted 101,483 units of Ordinary Shares, increasing direct ownership by 2,016% to 106,518 units (SEC Form 4)4 - IceCure Medical Ltd. (0001584371) (Issuer)
- INSIDERVP, Human Resources Dotan Merav Nir was granted 73,890 units of Ordinary Shares, increasing direct ownership by 3,244% to 76,168 units (SEC Form 4)4 - IceCure Medical Ltd. (0001584371) (Issuer)
- INSIDERSEC Form 4 filed by Director Chan Vincent Chun Hung4 - IceCure Medical Ltd. (0001584371) (Issuer)
- INSIDERChief Financial Officer Peleg Meir was granted 181,483 units of Ordinary Shares, increasing direct ownership by 1,361% to 194,816 units (SEC Form 4)4 - IceCure Medical Ltd. (0001584371) (Issuer)
- INSIDERChief Operating Officer Levav Shay was granted 141,483 units of Ordinary Shares, increasing direct ownership by 2,935% to 146,303 units (SEC Form 4)4 - IceCure Medical Ltd. (0001584371) (Issuer)
- SECSEC Form S-8 filed by IceCure Medical Ltd.S-8 - IceCure Medical Ltd. (0001584371) (Filer)
- SECSEC Form POS AM filed by IceCure Medical Ltd.POS AM - IceCure Medical Ltd. (0001584371) (Filer)
- SECSEC Form POS AM filed by IceCure Medical Ltd.POS AM - IceCure Medical Ltd. (0001584371) (Filer)
- PRIceCure Highlights Two New Peer-Reviewed Publications Supporting Cryoablation in Breast Cancer Treatment De-EscalationNew review by leading U.S. experts highlights ProSense® FDA marketing authorization, updated American Society of Breast Surgeons guidelines, and encouraging outcomes from the five-year ICE3 clinical trial while a second publication extends cryoablation's clinical role to axillary lymph node metastasesCAESAREA, Israel, Aug. 13, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today highlighted two recent peer-reviewed publications by leading U.S. experts that reinforce the growing clinical role of cryoablation
- SECSEC Form 6-K filed by IceCure Medical Ltd.6-K - IceCure Medical Ltd. (0001584371) (Filer)
- PRIceCure Reports its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-Over-YearThe Company is advancing commercial execution and expanding its U.S. commercial footprint through approximately 70% growth in its active installed base following U.S. Food and Drug Administration's ("FDA") clearance, driving long-term value creation and supported by a strong cash positionCAESAREA, Israel, Aug. 12, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today reported financial and operational results as of and for the six months ended June 30, 2026. "We believe IceCure has reached an important inflec
- SECSEC Form 6-K filed by IceCure Medical Ltd.6-K - IceCure Medical Ltd. (0001584371) (Filer)
- SECSEC Form 6-K filed by IceCure Medical Ltd.6-K - IceCure Medical Ltd. (0001584371) (Filer)
- PRIceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing "ChoICE" Study for Low-Risk Breast Cancer Cryoablation TreatmentAdventist Health Glendale is the first site able to enroll patients in the ChoICE Study after signing both an agreement and receiving IRB approvalThe site will be led by breast surgeon, Dr. Dennis Holmes, MD, FACS, a recognized leader in breast cancer cryoablation CAESAREA, Israel, August 6, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that Adventist Health Glendale in Glendale, California has signed an agreement and received approval from the Institutional Review Board to become the first
- PRIceCure Medical to Report First Half 2026 Financial and Operating Results on August 12, 2026CAESAREA, Israel, Aug. 5, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it will issue a press release with its financial and operational results as of and for the six months ended June 30, 2026 before the Nasdaq Stock Market opens on Wednesday, August 12, 2026. The Company will also discuss such results and other corporate developments on a conference call at 10:00 a.m. EDT on the same day. Conference call & webcast info:W
- PRIceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense®The petition by The Society of Interventional Oncology (SIO) includes adding criteria for patients aged 50-69 who are poor surgical candidates or who decline surgery in the National Comprehensive Cancer Network (NCCN) treatment guidelines, expanding the current eligible population of patients aged 70 and aboveCAESAREA, Israel, July 29, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that the Society of Interventional Oncology ("SIO") has submitted a formal petition (the "SIO Petition") to the
- PRIceCure Medical Kicks Off its Post-Marketing "ChoICE" Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical SiteCompany signed agreement with the West Cancer Center & Research Institute, the first clinical site for its post-marketing study for ProSense® cryoablation in the treatment of low-risk breast cancer CAESAREA, Israel, July 27, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that the West Cancer Center & Research Institute in Germantown, Tennessee will serve as the first U.S. clinical site for the Company's post-marketing study "ChoICE," (the "ChoICE Study"), for ProSense® in the treatment of low
- PRIceCure Expands U.S. Commercial Team to Meet Surging Demand for ProSense® CryoablationCAESAREA, Israel, July 14, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive liquid nitrogen-based cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced the expansion of its United States ("U.S.") sales and marketing teams. In response to strong demand from leading hospitals and physicians across the country, the Company has strengthened its commercial team with new dedicated sales and marketing professionals in key territories such as New York, Southern California and the Midwest. The Company has also added additional clinical support to train and
ICCM FAQ
6 questionsWhat does IceCure Medical Ltd. do?
IceCure Medical Ltd develops and markets minimally invasive cryoablation therapies for women's health and oncology markets. It offers ProSense system, a cryoablation solution for breast tumors. The company was founded in 2006 and is headquartered in Caesarea, Israel.Where does ICCM stock trade?
IceCure Medical Ltd. (ICCM) is listed on NASDAQ.What sector and industry is ICCM in?
IceCure Medical Ltd. operates in the Health Care sector, Medical/Dental Instruments industry.What are analysts saying about ICCM?
IceCure Medical Ltd. has had 2 recent analyst actions on file. The most recent action was from Brookline Capital: Buy with a $565.00 price target on 2022-02-02. Recent price targets range from $565.00 to $1450.00.What companies are similar to ICCM?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare ICCM side-by-side with any of them on Quantisnow.How can I track ICCM on Quantisnow?
Quantisnow aggregates IceCure Medical Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ICCM to receive live email and push alerts on every new disclosure.